Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank50
3Y CAGR-50.0%
5Y CAGR-26.4%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
-50.0%/yr
vs +69.9%/yr prior
5Y CAGR
-26.4%/yr
Recent deceleration
Acceleration
-120.0pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
4 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $6.59M | -40.5% |
| 2024 | $11.07M | -68.4% |
| 2023 | $35.05M | -33.7% |
| 2022 | $52.83M | -15.0% |
| 2021 | $62.18M | +104.4% |
| 2020 | $30.42M | +168.1% |
| 2019 | $11.35M | +79.1% |
| 2018 | $6.34M | +18.1% |
| 2017 | $5.37M | -3.7% |
| 2016 | $5.57M | - |